It's like playing Battleship with the prostate. Every hole that we have has a coordinate, and we can place the needle through that. We have a picture that overlays and shows us the prostate and where that biopsy's being taken from. Then, we can basically look at the picture when we get a positive biopsy back and see exactly where the cancer is in the gland.

Unfortunately, we're finding that [the TRUS biopsy] is really not very effective at all. When you look at the statistics of a normal size gland the chances of actually finding that tumor are about 15 percent. So, 85 percent of patients by that biopsy method may be missing their cancer.

A lot of patients are being treated inappropriately with the wrong therapies because they're either under-diagnosed or over-diagnosed.